COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

An open-label, Phase 2a/2b study of KRT-232 in subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post PV-MF), or Post Essential Thrombocythemia MF (Post ET-MF) who have failed prior treatment with a JAK inhibitor

Protocol No
KARTOS-KRT-232-101-MF
Principal Investigator
Laura Michaelis
Phase
II
Summary
This study wants to find out whether the investigational drug, KRT-232, reduces the symptoms of myelofibrosis, and whether it causes any problems (side effects).
Description
KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL
Sub Category
Hematologic/Blood Related Cancers
ClinicalTrials.gov
go to website